Lupus nephritis |
Prediction of clinical response |
miR-31, miR-107, and miR-135b-5p ↑ |
57 pts |
[81] |
|
Disease flare |
let-7a and miR-21 ↓ |
34 pts |
[79] |
|
Cellular crescent formation in type IV lupus nephritis |
miR-3135b, miR-654-5p, and miR-146a-5p ↑ |
14 pts-3 ctrs |
[80] |
|
IgA nephropathy |
Tubulointerstitial inflammation and C3 deposition |
CCL2 mRNA ↑ |
55 pts-24 ctrs |
[76] |
|
Nephropathy in type 1 diabetes |
Various degrees of albuminuria |
Various differentially expressed miRNAs |
48 pts |
[56] |
|
Nephropathy in type 2 diabetes |
Decline in renal function |
Uromodulin mRNA ↑ |
242 pts and ctrs |
[57] |
|
Progression of albuminuria |
C-megalin |
33 pts-11 ctrs |
[58] |
|
Macroalbuminuria |
miR-362-3p, miR-877-3p, and miR-150-5p ↑; urinary miR-15a-5p ↓ |
5 pts-5 ctrs |
[106] |
|
AL amyloidosis |
Active amyloid formation |
Light chain oligomers |
4 pts-1 ctr |
[71] |
|
|
|
13 pts-1 ctr |
[72] |
|
Autosomal dominant polycystic kidney disease |
eGFR decline |
AQP-2 ↓; APO-A1 ↑ |
46 pts-11 ctrs |
[85] |
|
Cystinuria |
eGFR value |
165 differentially expressed proteins |
8 pts-10 ctrs |
[90] |